Diseases (50)

Diagnostic Testing (41)

Note:

Rule out hepatitis B virus infection.


Note:

Rule out Hepatitis B.


Note:

Rule out hepatitis B.


Note:

Differential diagnosis of HBV infection.


Note:

Rule out hepatitis B virus infection.


Note:

R/O Hepatitis B


Note:

Differential diagnosis of hepatitis B viral infection.


Note:

In patients considered for rituximab therapy.


Note:

Rule out hepatitis B infection.


Note:

Rule out Hepatitis B caused cryoglobulinemia.


Note:

Rule out hepatitis B.


Note:

Rule out hepatitis B infection in patients using needles.


Note:

Screening for infection with Hepatitis B virus due to dialysis.


Note:

Rule out hepatitis B infection.


Note:

Rule out hepatitis B infection.


Note:

If evidence of liver disease is present.


Note:

R/O Viral hepatitis in patients with evidence of hepatocellular injury


Note:

Rule out hepatitis B.


Note:

Rule out hepatitis B.


Note:

Rule out hepatitis B infection in patients using IV heroin.


Note:

Rule out hepatitis B.


Note:

Rule out Hepatitis B virus infection.


Note:

Rule out vasculitis caused by hepatitis B.


Note:

Rule out hepatitis B.


Note:

Rule out hepatitis B infection.


Note:

Rule out hepatitis B.

Other Supportive/Alternative Tests (1)

Note:

Hepatitis B testing should be ordered in patients for whom rituximab is being considered.

Overview

Hepatitis B infection is caused by the Hepatitis B Virus. Hepatitis B virus is spread by contact with contaminated blood and body fluids. Chronic infection with Hepatitis B virus results in damage to the liver, cirrhosis and/or liver cancer. The body’s immune system is responsible for the liver tissue damage because it destroys the liver cells containing the virus. Consumption of alcohol during infection with Hepatitis B virus is discouraged because it can increase the damage to the liver. Hepatitis B virus is prevented by cautious and safe handling of blood and body fluids, vaccination, and refraining from behavior known to be associated with acquisition of the virus. Serology testing to detect hepatitis B surface antigen (HBsAg) is the standard for diagnosing the disease.

In hepatitis B virus infection, surface antigen is detectable 2 – 5 weeks before onset of symptoms, rises in titer, and peaks at about the time of onset of clinical illness. Generally it persists for 1 – 5 months, declining in titer and disappearing with resolution of clinical symptoms. HBsAg is a first-line test for the diagnosis of acute or chronic hepatitis B. If positive, no other test is needed. HBsAg is an indicator for active infection. It is a marker used for detecting initial infection, monitoring the course of the infection, and progression to chronic disease. It is also used in the screening of donor blood.

Clinical Utility

  • Diagnosis of HBV infection
  • Diagnosis of HBV active infection
  • Monitoring the course of the infection and progression to chronic disease
  • Blood donor screening

Interpretation

Positive in:

  • Acute hepatitis B
  • Chronic hepatitis B (persistence of HBsAg for >6 months)
  • HBsAg-positive carriers

Note: In rare cases HBsAg might be negative (when tested early). If clinical suspicion is high, HBcAb (IgM) test is then indicated.

Reference Ranges

Negative (Non-reactive)

 

Methodology

Enzyme immunoassay, Chemiluminescence immunoassay.

Specimen Collection

Serum (SST) or Plasma EDTA (Lavender) or Plasma Heparin

Stability:

  • Ambient: 5 days
  • Refrigerated: 14 days
  • Frozen: 60 days

Additional Testing

HBsAg is definitive for diagnosing infection with Hepatitis B Virus. Other tests useful in monitoring HBV Infection: Total Anti-HBc, HBeAg, HBV DNA, Liver Function Tests, Lactate Dehydrogenase, Liver Biopsy.

Turnaround Time

1-3 days.

CPT

87340

LOINC

ICD10

A15Respiratory tuberculosis
A15.0Tuberculosis of lung
A17Tuberculosis of nervous system
A18Tuberculosis of other organs
A18.11Tuberculosis of kidney and ureter
A19Miliary tuberculosis
A19.0Acute miliary tuberculosis of a single specified site
A19.1Acute miliary tuberculosis of multiple sites
A19.2Acute miliary tuberculosis, unspecified
A19.9Miliary tuberculosis, unspecified
B02.23Postherpetic polyneuropathy
B15Acute hepatitis A
B16Acute hepatitis B
B16.9Acute hepatitis B without delta-agent and without hepatic coma
B17Other acute viral hepatitis
B17.0Acute delta-(super) infection of hepatitis B carrier
B17.8Other specified acute viral hepatitis
B18Chronic viral hepatitis
B18.0Chronic viral hepatitis B with delta-agent
B18.1Chronic viral hepatitis B without delta-agent
B18.9Chronic viral hepatitis, unspecified
B19Unspecified viral hepatitis
B19.0Unspecified viral hepatitis with hepatic coma
B19.1Unspecified viral hepatitis B
B19.10Unspecified viral hepatitis B without hepatic coma
B19.11Unspecified viral hepatitis B with hepatic coma
B19.9Unspecified viral hepatitis without hepatic coma
B90Sequelae of tuberculosis
C22Malignant neoplasm of liver and intrahepatic bile ducts
C22.0Liver cell carcinoma
C22.1Intrahepatic bile duct carcinoma
C22.8Malignant neoplasm of liver, primary, unspecified as to type
C22.9Malignant neoplasm of liver, not specified as primary or secondary
C24.0Malignant neoplasm of extrahepatic bile duct
C77Secondary and unspecified malignant neoplasm of lymph nodes
C77.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C77.9Secondary and unspecified malignant neoplasm of lymph node, unspecified
C82Follicular lymphoma
C82.89Other types of follicular lymphoma, extranodal and solid organ sites
C82.90Follicular lymphoma, unspecified, unspecified site
C82.99Follicular lymphoma, unspecified, extranodal and solid organ sites
C83.1Mantle cell lymphoma
C83.10Mantle cell lymphoma, unspecified site
C83.11Mantle cell lymphoma, lymph nodes of head, face, and neck
C83.12Mantle cell lymphoma, intrathoracic lymph nodes
C83.13Mantle cell lymphoma, intra-abdominal lymph nodes
C83.14Mantle cell lymphoma, lymph nodes of axilla and upper limb
C83.15Mantle cell lymphoma, lymph nodes of inguinal region and lower limb
C83.16Mantle cell lymphoma, intrapelvic lymph nodes
C83.17Mantle cell lymphoma, spleen
C83.18Mantle cell lymphoma, lymph nodes of multiple sites
C83.19Mantle cell lymphoma, extranodal and solid organ sites
C83.3Diffuse large B-cell lymphoma
C83.30Diffuse large B-cell lymphoma, unspecified site
C85.90Non-Hodgkin lymphoma, unspecified, unspecified site
D13Benign neoplasm of other and ill-defined parts of digestive system
D13.4Benign neoplasm of liver
D13.5Benign neoplasm of extrahepatic bile ducts
D69Purpura and other hemorrhagic conditions
D69.3Immune thrombocytopenic purpura
D69.4Other primary thrombocytopenia
D69.6Thrombocytopenia, unspecified
D69.8Other specified hemorrhagic conditions
D89.1Cryoglobulinemia
F11Opioid related disorders
F11.1Opioid abuse
F11.10Opioid abuse, uncomplicated
F11.12Opioid abuse with intoxication
F11.2Opioid dependence
F11.20Opioid dependence, uncomplicated
F11.21Opioid dependence, in remission
F11.9Opioid use, unspecified
F11.90Opioid use, unspecified, uncomplicated
F11.92Opioid use, unspecified with intoxication
F13.1Sedative, hypnotic or anxiolytic-related abuse
F15.1Other stimulant abuse
F19Other psychoactive substance related disorders
F19.1Other psychoactive substance abuse
F19.10Other psychoactive substance abuse, uncomplicated
F19.2Other psychoactive substance dependence
F19.20Other psychoactive substance dependence, uncomplicated
F19.9Other psychoactive substance use, unspecified
F55Abuse of non-psychoactive substances
G58.9Mononeuropathy, unspecified
G60Hereditary and idiopathic neuropathy
G60.0Hereditary motor and sensory neuropathy
G60.3Idiopathic progressive neuropathy
G60.8Other hereditary and idiopathic neuropathies
G61Inflammatory polyneuropathy
G61.1Serum neuropathy
G62Other and unspecified polyneuropathies
G62.9Polyneuropathy, unspecified
G63Polyneuropathy in diseases classified elsewhere
G90.0Idiopathic peripheral autonomic neuropathy
G99Other disorders of nervous system in diseases classified elsewhere
G99.0Autonomic neuropathy in diseases classified elsewhere
I12Hypertensive chronic kidney disease
I12.0Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease
I13Hypertensive heart and chronic kidney disease
I77Other disorders of arteries and arterioles
I77.6Arteritis, unspecified
K65.1Peritoneal abscess
K70Alcoholic liver disease
K70.0Alcoholic fatty liver
K70.1Alcoholic hepatitis
K70.10Alcoholic hepatitis without ascites
K70.11Alcoholic hepatitis with ascites
K70.9Alcoholic liver disease, unspecified
K71Toxic liver disease
K71.3Toxic liver disease with chronic persistent hepatitis
K71.9Toxic liver disease, unspecified
K72Hepatic failure, not elsewhere classified
K72.0Acute and subacute hepatic failure
K72.00Acute and subacute hepatic failure without coma
K72.01Acute and subacute hepatic failure with coma
K72.11Chronic hepatic failure with coma
K72.90Hepatic failure, unspecified without coma
K72.91Hepatic failure, unspecified with coma
K73Chronic hepatitis, not elsewhere classified
K73.9Chronic hepatitis, unspecified
K74Fibrosis and cirrhosis of liver
K74.0Hepatic fibrosis
K74.6Other and unspecified cirrhosis of liver
K74.60Unspecified cirrhosis of liver
K74.69Other cirrhosis of liver
K75Other inflammatory liver diseases
K75.0Abscess of liver
K75.81Nonalcoholic steatohepatitis (NASH)
K76Other diseases of liver
K76.0Fatty (change of) liver, not elsewhere classified
K76.3Infarction of liver
K76.89Other specified diseases of liver
K76.9Liver disease, unspecified
K77Liver disorders in diseases classified elsewhere
L93Lupus erythematosus
M05.2Rheumatoid vasculitis with rheumatoid arthritis
M25.48Effusion, other site
M30Polyarteritis nodosa and related conditions
M30.0Polyarteritis nodosa
M30.1Polyarteritis with lung involvement [Churg-Strauss]
M30.8Other conditions related to polyarteritis nodosa
M31.1Thrombotic microangiopathy
M31.3Wegener's granulomatosis
M31.30Wegener's granulomatosis without renal involvement
M31.31Wegener's granulomatosis with renal involvement
M31.4Aortic arch syndrome [Takayasu]
M32Systemic lupus erythematosus (SLE)
M32.0Drug-induced systemic lupus erythematosus
N00Acute nephritic syndrome
N00.3Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
N00.8Acute nephritic syndrome with other morphologic changes
N00.9Acute nephritic syndrome with unspecified morphologic changes
N02.8Recurrent and persistent hematuria with other morphologic changes
N03Chronic nephritic syndrome
N03.2Chronic nephritic syndrome with diffuse membranous glomerulonephritis
N03.5Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
N03.7Chronic nephritic syndrome with diffuse crescentic glomerulonephritis
N03.9Chronic nephritic syndrome with unspecified morphologic changes
N04Nephrotic syndrome
N04.8Nephrotic syndrome with other morphologic changes
N04.9Nephrotic syndrome with unspecified morphologic changes
N05Unspecified nephritic syndrome
N05.2Unspecified nephritic syndrome with diffuse membranous glomerulonephritis
N05.5Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
N08Glomerular disorders in diseases classified elsewhere
N13Obstructive and reflux uropathy
N18Chronic kidney disease (CKD)
N18.6End stage renal disease
N18.9Chronic kidney disease, unspecified
N23Unspecified renal colic
N26.9Renal sclerosis, unspecified
O09Supervision of high risk pregnancy
O09.3Supervision of pregnancy with insufficient antenatal care
O26Maternal care for other conditions predominantly related to pregnancy
O28Abnormal findings on antenatal screening of mother
O28.9Unspecified abnormal findings on antenatal screening of mother
O36.01Maternal care for anti-D [Rh] antibodies
O99.01Anemia complicating pregnancy
O99.280Endocrine, nutritional and metabolic diseases complicating pregnancy, unspecified trimester
P58Neonatal jaundice due to other excessive hemolysis
P59.0Neonatal jaundice associated with preterm delivery
P59.9Neonatal jaundice, unspecified
R16Hepatomegaly and splenomegaly, not elsewhere classified
R17Unspecified jaundice
R18Ascites
R18.8Other ascites
R19Other symptoms and signs involving the digestive system and abdomen
R19.0Intra-abdominal and pelvic swelling, mass and lump
R43.0Anosmia
R74.0Nonspecific elevation of levels of transaminase and lactic acid dehydrogenase [LDH]
R77Other abnormalities of plasma proteins
R78Findings of drugs and other substances, not normally found in blood
R78.1Finding of opiate drug in blood
R78.2Finding of cocaine in blood
R78.4Finding of other drugs of addictive potential in blood
R78.5Finding of other psychotropic drug in blood
R94Abnormal results of function studies
R94.4Abnormal results of kidney function studies
R94.5Abnormal results of liver function studies
T39.1Poisoning by, adverse effect of and underdosing of 4-Aminophenol derivatives
T39.1X1Poisoning by 4-Aminophenol derivatives, accidental (unintentional)
T39.1X2Poisoning by 4-Aminophenol derivatives, intentional self-harm
T39.1X3Poisoning by 4-Aminophenol derivatives, assault
T39.1X4Poisoning by 4-Aminophenol derivatives, undetermined
T40.2X5Adverse effect of other opioids
T42.4X5AAdverse effect of benzodiazepines, initial encounter
T86.4Complications of liver transplant
T86.40Unspecified complication of liver transplant
T86.41Liver transplant rejection
T86.42Liver transplant failure
T86.43Liver transplant infection
T86.49Other complications of liver transplant
Z00Encounter for general examination without complaint, suspected or reported diagnosis
Z00.0Encounter for general adult medical examination
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.8Encounter for other general examination
Z01.41Encounter for routine gynecological examination
Z01.411Encounter for gynecological examination (general) (routine) with abnormal findings
Z01.83Encounter for blood typing
Z01.84Encounter for antibody response examination
Z11.1Encounter for screening for respiratory tuberculosis
Z12.10Encounter for screening for malignant neoplasm of intestinal tract, unspecified
Z13.1Encounter for screening for diabetes mellitus
Z13.220Encounter for screening for lipoid disorders
Z13.6Encounter for screening for cardiovascular disorders
Z20Contact with and (suspected) exposure to communicable diseases
Z20.5Contact with and (suspected) exposure to viral hepatitis
Z22.50
Z22.59
Z30.014Encounter for initial prescription of intrauterine contraceptive device
Z30.8Encounter for other contraceptive management
Z32.0Encounter for pregnancy test
Z34Encounter for supervision of normal pregnancy
Z34.8Encounter for supervision of other normal pregnancy
Z34.9Encounter for supervision of normal pregnancy, unspecified
Z34.90Encounter for supervision of normal pregnancy, unspecified, unspecified trimester
Z36Encounter for antenatal screening of mother
Z48.23Encounter for aftercare following liver transplant
Z67Blood type
Z68Body mass index [BMI]
Z71.5Drug abuse counseling and surveillance
Z71.51Drug abuse counseling and surveillance of drug abuser
Z71.52Counseling for family member of drug abuser
Z77Other contact with and (suspected) exposures hazardous to health
Z77.120Contact with and (suspected) exposure to mold (toxic)
Z84Family history of other conditions
Z85Personal history of malignant neoplasm
Z85.05Personal history of malignant neoplasm of liver
Z85.09Personal history of malignant neoplasm of other digestive organs
Z85.72Personal history of non-Hodgkin lymphomas
Z86.11Personal history of tuberculosis
Z94.4Liver transplant status

References

  • Gut. 2011 Dec 16. [PMID:22180061]
  • Hosp Med. 2002;63:16. [PMID:11828810]
  • Am J Gastroenterol. 2006;101(Suppl):S1. [PMID:16448446]
  • Am J Med. 2005;118 (Suppl 10A):28S. [PMID:16271538]
  • Clin Liver Dis. 2004;8:267. [PMID:15481340]
  • Gastroenterol Clin Biol. 2008 Jan;32(1 Pt 2):S56-63. [PMID:18662611]
  • N Engl J Med. 2004 Mar 11;350(11):1118-29. [PMID:15014185]
  • Stevens, CD. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company (2010).
  • Burtis C, Ashwood E, and Bruns D. Fundamentals of Clinical Chemistry. St. Louis: Saunders (2008).